- Cigna coverage for Wegovy varies by plan — employer-sponsored, marketplace, and Cigna+Oscar plans each have different formularies and rules
- Some Cigna plans have step therapy requirements, meaning you may need to try other weight management approaches before Wegovy is approved
- Prior authorization is typically required, with documentation of BMI, comorbidities, and clinical evaluation
- PEAK handles Cigna benefits verification and prior authorization so you know your coverage status before starting treatment
Note: PEAK accepts Cigna commercial plans. We do not accept Cigna Medicare Advantage or Cigna Medicaid managed care plans.
Cigna and Wegovy overview
Cigna is one of the largest health insurers in Virginia and across the country. Whether your Cigna plan covers Wegovy (semaglutide) for chronic weight management depends on your specific plan design, your employer’s benefits decisions, and the formulary your plan uses.
There is no single Cigna-wide policy on Wegovy. Cigna administers hundreds of different plan configurations, each with its own drug formulary, exclusion list, and prior authorization criteria. Two patients with Cigna cards sitting in the same waiting room can have completely different coverage outcomes.
What we can tell you from working with Cigna plans regularly: coverage for Wegovy has expanded over the past year, but it remains plan-specific. The only reliable way to know is to verify your individual benefits — which is something our team does before your first appointment.
Wegovy (semaglutide 2.4 mg) was FDA-approved for chronic weight management in June 2021 and received a supplemental approval for cardiovascular risk reduction in March 2024. These are two distinct indications, and Cigna may evaluate coverage differently depending on which indication your clinician uses.
Plan types and formulary differences
Your Cigna plan type is the single biggest factor in determining whether Wegovy is covered. Here is how the major plan categories differ:
Employer-sponsored plans
Most Cigna members in Virginia receive coverage through an employer. These plans vary widely because employers choose which benefits to include. Large employers with self-funded plans have full control over whether anti-obesity medications appear on their formulary. Some have added Wegovy; many have not. If your employer has opted to exclude weight loss medications, Cigna will enforce that exclusion regardless of medical necessity.
ACA marketplace plans
Cigna offers individual and family plans through the ACA marketplace in select states. These plans must cover essential health benefits, but anti-obesity medications are not classified as an essential health benefit under the ACA. Coverage for Wegovy on marketplace plans is inconsistent and often limited to specific tiers or subject to high cost-sharing.
Cigna+Oscar plans
Cigna+Oscar is a joint venture offering individual and small group plans in certain markets. These plans have their own distinct formulary, which may differ from standard Cigna plans. If you are on a Cigna+Oscar plan, your Wegovy coverage must be verified against that plan’s specific drug list rather than Cigna’s standard formulary.
Even when Wegovy is covered, the formulary tier determines your cost. Preferred brand-name tier placement means lower copays. Non-preferred or specialty tier placement means significantly higher out-of-pocket costs. Some Cigna plans place Wegovy on a specialty tier with coinsurance rather than a flat copay.
Prior authorization requirements
Nearly all Cigna plans that cover Wegovy require prior authorization (PA) before the medication will be approved. This is a process where your prescribing clinician submits clinical documentation to Cigna demonstrating that Wegovy is medically necessary for you.
Cigna’s typical PA requirements for Wegovy include:
- BMI documentation — Documented BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea
- Comorbidity documentation — If your BMI is between 27 and 30, your clinician must provide clinical evidence of at least one qualifying comorbidity and explain why weight reduction would improve that condition
- Clinical evaluation — Documentation of a thorough clinical evaluation, including weight history, prior weight management attempts, and current health status
- Prescriber qualifications — The prescriber must have appropriate authority and, in some plans, must be a specialist or part of a weight management program
Prior authorization is a documentation requirement, not a denial. The quality and completeness of your clinician’s submission is often the difference between approval and rejection.
At PEAK, our clinical team structures every initial evaluation with PA requirements in mind. We document your BMI, comorbidities, weight history, and treatment rationale in the format Cigna expects because we submit these requests regularly.
Step therapy requirements
Some Cigna plans require step therapy before approving Wegovy. Step therapy — sometimes called “fail first” — means your plan requires you to try one or more alternative weight management approaches before Wegovy will be covered.
Common step therapy requirements on Cigna plans include:
- Documented lifestyle modification — Evidence of participation in a structured diet and exercise program for a defined period, typically 3 to 6 months
- Trial of a lower-cost medication — Some Cigna plans require you to try another FDA-approved weight loss medication (such as phentermine, orlistat, or naltrexone-bupropion) before Wegovy is authorized
- Behavioral counseling — Documentation of participation in a behavioral health or nutrition counseling program
How to meet step therapy requirements
If your Cigna plan has step therapy requirements, your clinician can help you meet them efficiently. This does not mean you need to start from scratch. If you have already tried other weight loss methods — even before coming to PEAK — those prior attempts may count. Your clinician can document your history and submit it as evidence that step therapy criteria have been satisfied.
Step therapy exceptions
Cigna allows step therapy exceptions in certain circumstances. Your clinician can request an exception if there is a documented clinical reason why the required step therapy would be ineffective, harmful, or medically inappropriate for you. Common grounds for exceptions include contraindications to required first-line medications, prior adverse reactions, or clinical urgency related to weight-associated comorbidities.
We identify step therapy requirements during benefits verification — before your first clinical visit. If your plan requires it, we develop a plan to either satisfy the requirement efficiently or request an exception with supporting documentation. Either way, you will know what to expect before you start.
The cardiovascular pathway
In March 2024, the FDA approved Wegovy for a second indication: reducing the risk of major adverse cardiovascular events (MACE) in adults with established cardiovascular disease (CVD) and either overweight or obesity. This approval was based on the SELECT trial, which demonstrated a statistically significant reduction in cardiovascular events.
This second indication creates an alternative coverage pathway through Cigna. If you have documented cardiovascular disease — such as a history of heart attack, stroke, or peripheral arterial disease — your clinician may be able to submit the prior authorization under the cardiovascular indication rather than the chronic weight management indication.
This matters because some Cigna plans that exclude weight loss medications may still cover medications prescribed for cardiovascular risk reduction. The cardiovascular pathway can bypass weight loss plan exclusions entirely when it applies.
The cardiovascular indication is a legitimate, FDA-approved use of Wegovy supported by a major clinical trial. Your clinician must document genuine cardiovascular disease. At PEAK, we evaluate every patient completely, and when CVD is present, we use the most clinically appropriate pathway for both treatment and coverage.
Appeals process
If Cigna denies your prior authorization for Wegovy, you have the right to appeal. Understanding Cigna’s specific appeals process and timelines can significantly improve your chances of a successful outcome.
Cigna’s appeal levels
- First-level appeal — A formal request for Cigna to re-review the denial with additional documentation. Your clinician submits a detailed letter of medical necessity along with any new clinical evidence. Cigna must respond within 30 days for standard appeals or 72 hours for expedited (urgent) appeals.
- Peer-to-peer review — Your prescribing clinician can request a direct phone conversation with Cigna’s medical director to present your case. Peer-to-peer reviews often overturn initial denials when documentation is strong and the clinician can articulate the medical rationale clearly.
- External review — If Cigna upholds the denial after internal appeals, you can request an independent external review through your state’s insurance regulatory process. An independent reviewer outside of Cigna evaluates whether the denial was medically appropriate.
Documentation for appeals
Successful appeals typically include detailed clinical notes, updated BMI and lab results, documentation of comorbidities, evidence of prior weight management attempts, and a clear explanation of why Wegovy is the most appropriate treatment option. The more specific and thorough the documentation, the stronger the appeal.
Cigna has defined deadlines for each appeal level. Missing a filing deadline can forfeit your appeal rights. At PEAK, we track every PA submission and denial, and we file appeals within the required timeframes so you do not lose your right to challenge a denial.
Manufacturer savings programs
Novo Nordisk, the manufacturer of Wegovy, offers a savings card program for eligible commercially insured patients. If your Cigna plan covers Wegovy, the manufacturer savings card can be used alongside your insurance to reduce your out-of-pocket costs further.
Key details about stacking savings with Cigna coverage:
- Commercial insurance required — The savings card is available to patients with commercial insurance (including employer-sponsored and marketplace plans). It is not available to patients on Medicare, Medicaid, or other government-funded programs.
- Reduces copay or coinsurance — The savings card applies after your insurance processes the claim, reducing whatever out-of-pocket amount remains. This can bring a high copay or specialty-tier coinsurance down significantly.
- Eligibility and terms change — Manufacturer savings programs are updated periodically. PEAK’s team stays current on available programs and can help you determine whether you qualify at the time of your prescription.
How PEAK handles Cigna
Working through Cigna’s formulary, prior authorization requirements, and step therapy rules is one of the most common challenges patients face when starting Wegovy. At PEAK, we handle it before you walk through the door.
Here is what our process looks like:
- Benefits verification. We check your Cigna plan for Wegovy coverage, formulary tier, step therapy requirements, and any exclusions — before your first appointment.
- Prior authorization. Our clinical team prepares and submits your PA with the documentation Cigna requires. We structure our clinical notes specifically for Cigna’s criteria because we work with their plans regularly.
- Step therapy navigation. If your plan requires step therapy, we identify whether your history already satisfies it or whether an exception request is appropriate.
- Denial management. If your PA is denied, we manage the appeal process — including peer-to-peer reviews, formal appeals, and external review requests.
- Alternative pathways. If Wegovy is not covered under your Cigna plan, we evaluate other FDA-approved options that may be on your formulary, including Zepbound, Saxenda, or Contrave.
We tell you what your Cigna plan covers before you commit to anything. If your plan does not cover the medication you need, we will tell you that directly — along with what your options are.
